P
Purple Biotech Ltd D
D
PPBT
4.20000
USD
-0.24
(-5.41%)
Market Open
Volume
110
EPS
-19
Div Yield
-
P/E
-0
Market Cap
37,927,886
Title: Purple Biotech Ltd.
Sector: Healthcare
Industry: Biotechnology
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.